Live Estimate
Weight of the world
An estimated 15.5 million Americans are taking a GLP-1 right now. The counter below is our best-supported guess at what they have lost so far, ticking upward with every second the page is open.
Reviewed by the FormBlends Medical Review Team. Last reviewed .
Estimated pounds lost across America right now
and counting, every second
~565 lbs lost every minute
across an estimated 15.5 million Americans on GLP-1 medications
What the counter is, and what it is not
It is a transparent multiplication of a public utilization estimate and a conservative average weight-loss rate from the two large phase-3 GLP-1 trials. It is not a measurement, not a registry, and not a prediction.
The counter assumes a steady user base. In reality, new patients start every day, some discontinue, some switch products, and some regain weight after stopping. It also does not know whether any particular user is on a max dose, a maintenance dose, or a diabetes dose that tends to produce smaller weight changes.
We publish the formula, the sources, and the limitations together so the number stays arguable. If a better dataset appears, we update the constants. If the underlying research changes, we say so here.
Treat the counter as a reading aid. It converts "about 15 million people on a medication that tends to drive 15 to 22 percent weight loss" into a moving number your brain can actually feel. That is all, and that is the point.
Methodology and sources
Constant 1: estimated US adults on a GLP-1
We use 15,500,000. Three independent sources cluster tightly around this figure.
- KFF Health Tracking Poll, May 2024. Reported that 6% of US adults had used a GLP-1 for weight loss or diabetes. Applied to the Census estimate of about 258 million US adults, that gives roughly 15.5 million. The 15.5M figure in our model comes directly from this survey. KFF source
- Trilliant Health, January 2025. Estimated 15.2 million active GLP-1 prescriptions from claims data. Trilliant source
- IQVIA Institute, March 2025. Dispensing data placed the figure near 15.8 million. IQVIA source
Constant 2: average weight-loss rate per user
We use 0.368 lbs per week per user. This is a blended, conservative figure based on the two headline phase-3 trials.
- STEP 1 trial. Semaglutide 2.4 mg, 68 weeks. Mean weight loss of 14.9% of body weight at week 68. Wilding JPH, Batterham RL, Calanna S, et al. NEJM 2021; 384:989-1002. STEP 1 source
- SURMOUNT-1 trial. Tirzepatide 15 mg, 72 weeks. Mean weight loss of 22.5% of body weight at week 72. Jastreboff AM, Aronne LJ, Ahmad NN, et al. NEJM 2022; 387:205-216. SURMOUNT-1 source
At an approximately 60/40 market share (semaglutide/tirzepatide as of early 2025), weighted by max-dose trial results, a simple average lands closer to 0.45 to 0.50 lbs per week. We intentionally anchored lower because real-world adherence, dose titration over the first 16 weeks, and type 2 diabetes-indicated use pull the average down. The chosen rate is deliberately on the conservative side of the evidence.
Constant 3: anchor total
The anchor of 750,000,000 lbs as of is our estimate of the cumulative weight lost by all US GLP-1 users between the June 2021 approval of semaglutide 2.4 mg for chronic weight management and that anchor date. It is a rough integral of user-months over the adoption curve (roughly 40 million user-years at about 19.1 lbs per user per year), rounded toward a conservative round number.
Constant 4: derived per-second rate
The total seconds rate is 9.43 lbs per second, computed from the user count and the weekly rate.
total = anchor_lbs + (users x rate_per_sec x seconds_since_anchor) users = 15,500,000 rate_per_sec = 0.0000006085 lbs/sec/user total/sec = 9.43 lbs/sec anchor_lbs = 750,000,000 anchor_date = 2025-04-01T00:00:00Z
Named limitations
- No real-time data feed for collective weight loss exists. The counter is an estimate, not a measurement.
- The user count mixes obesity-indicated and type 2 diabetes patients. Diabetes-indicated users often see smaller weight changes.
- Dose titration over the first 12 to 16 weeks means early users lose less than the steady-state rate.
- The model assumes a flat user base. In practice, the population grows and churns.
- Some users discontinue and regain weight (STEP 4 extension, Rubino et al., JAMA 2021). The counter does not subtract regain.
- Compounded formulations are included in the user count and may have different real-world efficacy than brand-name products.
Frequently asked questions
Is the number on this counter real?
It is an estimate, not a measurement. No real-time registry of collective weight loss exists. The counter multiplies a public utilization figure (about 15.5 million US adults on a GLP-1, from KFF 2024) by a conservative blended loss rate derived from the STEP 1 and SURMOUNT-1 trials, then adds increments on the page. Treat it as an illustration, not a lab result.
How accurate is the estimate?
The user count is tight. KFF (May 2024), Trilliant Health (January 2025), and IQVIA (March 2025) all land in the 15.2 to 15.8 million range. The loss-rate side is broader. Maximum-dose trial results run higher than the 0.368 lbs per week we use, but real-world adherence, dose titration, and diabetes-indicated use pull the average down. We rounded toward the low end on purpose.
Why publish this if it is an estimate?
Because most numbers you see about GLP-1s come from marketing, not math. Publishing the formula, the sources, and the limitations in plain view is how you let people argue with the result. If a better source comes out, we update the constants. The counter is a reading aid for the published research, not a standalone claim.
Why does this matter?
Because scale changes the conversation. Individual weight loss is a private story. Fifteen million simultaneous weight losses is a public health event, and it reshapes surgery wait lists, cardiovascular outcomes, employer insurance math, and food-industry projections. Seeing the number move once a second makes the size of the shift harder to ignore.
Does the counter subtract weight regain?
No. When patients discontinue a GLP-1, weight regain is real, documented in the STEP 4 extension trial (Rubino et al., JAMA 2021). The current model assumes a steady user base and does not subtract regain. That is one of the documented limitations. A future version may model churn once there is reliable discontinuation data.
Where do the constants live in the code?
Every constant used in the formula is imported from /src/lib/weight-counter/model.ts: the user count, the weekly loss rate, the anchor timestamp, the anchor total, and the derived seconds rate. The model file is the single source of truth. Changes there update the counter, methodology section, and all derived values at once.
Related reading
The 6-Week Ozempic Plan: Real Weight Loss Results, Week by Week, From the Clinical Data
What Ozempic actually does in the first 6 weeks: average weight loss, why scale movement is small, and a realistic week-by-week plan.
6 Week Plan Ozempic Weight Loss Results: What Actually Happens and Why Most Timelines Are Wrong
Real 6-week Ozempic weight loss data from clinical trials, why week 2-3 shows minimal loss, and the dosing mistake that delays results by 4+ weeks.
2-Month Metformin Weight Loss Results: What the Clinical Data Actually Shows
Realistic 2-month metformin weight loss results from clinical data, why some people lose 4 to 6 pounds and others stall, plus a checklist if results are flat.
How to Reverse Prediabetes in 3 Months: The Evidence-Based Protocol That Works
The exact 12-week protocol to reverse prediabetes: weight loss targets, meal timing, exercise prescription, and when medication accelerates results.
How Long Does It Take for Semaglutide to Suppress Appetite?
Most patients notice appetite suppression within 2 to 5 days of their first semaglutide dose, with strongest effects at 2 to 3 weeks. Here's the full timeline.
Curious what your own number would look like?
A licensed provider can walk you through whether a GLP-1 is a reasonable option for your health and goals.
Start a free assessmentThis page is for informational and educational use only. It is not medical advice. The estimates shown are derived from published research and publicly available data, with limitations listed in the methodology section. GLP-1 receptor agonist medications are prescription drugs that require physician supervision. FormBlends does not diagnose, treat, cure, or prevent any disease. Individual results vary.